BR112022007240A2 - Método para produzir um anticorpo marcado com metal radioativo, anticorpo marcado com metal radioativo, conector de quelato, e, anticorpo modificado com peptídeo - Google Patents
Método para produzir um anticorpo marcado com metal radioativo, anticorpo marcado com metal radioativo, conector de quelato, e, anticorpo modificado com peptídeoInfo
- Publication number
- BR112022007240A2 BR112022007240A2 BR112022007240A BR112022007240A BR112022007240A2 BR 112022007240 A2 BR112022007240 A2 BR 112022007240A2 BR 112022007240 A BR112022007240 A BR 112022007240A BR 112022007240 A BR112022007240 A BR 112022007240A BR 112022007240 A2 BR112022007240 A2 BR 112022007240A2
- Authority
- BR
- Brazil
- Prior art keywords
- radioactive metal
- antibody
- peptide
- producing
- antibody labeled
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
- A61K51/0478—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group complexes from non-cyclic ligands, e.g. EDTA, MAG3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019191561 | 2019-10-18 | ||
| PCT/JP2020/039076 WO2021075546A1 (ja) | 2019-10-18 | 2020-10-16 | 放射性金属標識抗体の製造方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022007240A2 true BR112022007240A2 (pt) | 2022-07-05 |
Family
ID=75538111
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022007240A BR112022007240A2 (pt) | 2019-10-18 | 2020-10-16 | Método para produzir um anticorpo marcado com metal radioativo, anticorpo marcado com metal radioativo, conector de quelato, e, anticorpo modificado com peptídeo |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230248854A1 (https=) |
| EP (1) | EP4047010A4 (https=) |
| JP (2) | JPWO2021075546A1 (https=) |
| KR (1) | KR20220083768A (https=) |
| CN (1) | CN114555132A (https=) |
| AU (1) | AU2020367624A1 (https=) |
| BR (1) | BR112022007240A2 (https=) |
| CA (1) | CA3158344A1 (https=) |
| IL (1) | IL292312A (https=) |
| MX (1) | MX2022004588A (https=) |
| PH (1) | PH12022550919A1 (https=) |
| TW (1) | TWI875842B (https=) |
| WO (1) | WO2021075546A1 (https=) |
| ZA (1) | ZA202205154B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20230390425A1 (en) * | 2020-10-16 | 2023-12-07 | Nihon Medi-Physics Co., Ltd. | Radioactive complexes of anti-her2 antibody, and radiopharmaceutical |
| WO2022149578A1 (ja) | 2021-01-08 | 2022-07-14 | 日本メジフィジックス株式会社 | Ａｃ－２２５溶液の製造方法およびＡｃ－２２５溶液を用いた医薬の製造方法 |
| JPWO2022224980A1 (https=) * | 2021-04-20 | 2022-10-27 | ||
| EP4397320A1 (en) * | 2021-08-31 | 2024-07-10 | Nihon Medi-Physics Co., Ltd. | Radioactive complex of deglycosylated antibody and radioactive pharmaceutical product |
| JP2023135733A (ja) * | 2022-03-16 | 2023-09-29 | Ｊｆｅエンジニアリング株式会社 | ジルコニウム錯体およびその合成方法 |
| AU2023242087A1 (en) * | 2022-03-30 | 2024-09-12 | Nihon Medi-Physics Co., Ltd. | Method for producing complex |
| WO2024108304A1 (en) * | 2022-11-23 | 2024-05-30 | Standard Biotools Canada Inc. | Dithiol chelators for metal conjugation to antibodies |
| CN117466980A (zh) * | 2023-11-02 | 2024-01-30 | 浙江普罗亭健康科技有限公司 | 基于多肽链骨架应用于金属抗体标记的负载金属缀合物及其应用 |
| WO2025235681A1 (en) * | 2024-05-07 | 2025-11-13 | Cornell University | Halogenated metal chelators and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3160513B1 (en) * | 2014-06-30 | 2020-02-12 | Glykos Finland Oy | Saccharide derivative of a toxic payload and antibody conjugates thereof |
| ES3058443T3 (es) * | 2015-05-20 | 2026-03-10 | Univ Kagoshima | Modificación específica de anticuerpo con péptido de unión a IgG |
| DK3470418T3 (da) * | 2016-06-13 | 2024-09-30 | Univ Kagoshima | Site-specifik radioisotop-mærket antistof ved brug af using iggbindende peptid |
| JP7291395B2 (ja) * | 2017-06-16 | 2023-06-15 | 国立大学法人 鹿児島大学 | ＩｇＧ結合ペプチド、及び該ペプチドによる抗体の特異的修飾 |
| BR112020012099A2 (pt) | 2017-12-18 | 2020-11-17 | Janssen Biotech, Inc. | radiomarcação de polipeptídeos |
| SG11202009990UA (en) * | 2018-04-16 | 2020-11-27 | Nihon Mediphysics Co Ltd | Modified antibody and radioactive metal-labelled antibody |
-
2020
- 2020-10-16 JP JP2021552464A patent/JPWO2021075546A1/ja active Pending
- 2020-10-16 TW TW109135916A patent/TWI875842B/zh active
- 2020-10-16 BR BR112022007240A patent/BR112022007240A2/pt unknown
- 2020-10-16 EP EP20877197.2A patent/EP4047010A4/en active Pending
- 2020-10-16 WO PCT/JP2020/039076 patent/WO2021075546A1/ja not_active Ceased
- 2020-10-16 AU AU2020367624A patent/AU2020367624A1/en active Pending
- 2020-10-16 IL IL292312A patent/IL292312A/en unknown
- 2020-10-16 PH PH1/2022/550919A patent/PH12022550919A1/en unknown
- 2020-10-16 KR KR1020227016140A patent/KR20220083768A/ko active Pending
- 2020-10-16 CA CA3158344A patent/CA3158344A1/en active Pending
- 2020-10-16 CN CN202080072618.2A patent/CN114555132A/zh active Pending
- 2020-10-16 MX MX2022004588A patent/MX2022004588A/es unknown
- 2020-10-16 US US17/769,657 patent/US20230248854A1/en active Pending
-
2022
- 2022-05-10 ZA ZA2022/05154A patent/ZA202205154B/en unknown
-
2025
- 2025-07-22 JP JP2025122772A patent/JP2025157484A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220083768A (ko) | 2022-06-20 |
| CN114555132A (zh) | 2022-05-27 |
| WO2021075546A1 (ja) | 2021-04-22 |
| CA3158344A1 (en) | 2021-04-22 |
| US20230248854A1 (en) | 2023-08-10 |
| EP4047010A4 (en) | 2024-01-10 |
| IL292312A (en) | 2022-06-01 |
| TW202128732A (zh) | 2021-08-01 |
| MX2022004588A (es) | 2022-07-21 |
| TWI875842B (zh) | 2025-03-11 |
| ZA202205154B (en) | 2023-11-29 |
| PH12022550919A1 (en) | 2023-07-10 |
| JP2025157484A (ja) | 2025-10-15 |
| EP4047010A1 (en) | 2022-08-24 |
| JPWO2021075546A1 (https=) | 2021-04-22 |
| AU2020367624A1 (en) | 2022-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022007240A2 (pt) | Método para produzir um anticorpo marcado com metal radioativo, anticorpo marcado com metal radioativo, conector de quelato, e, anticorpo modificado com peptídeo | |
| Rogers et al. | Development of a quantitative mass spectrometry multi-attribute method for characterization, quality control testing and disposition of biologics | |
| Simpson et al. | Acetone precipitation of proteins and the modification of peptides | |
| MX2021001353A (es) | Constructos de anticuerpos para cldn18.2 y cd3. | |
| CO4410258A1 (es) | ANTICUERPOS MONOCLONALES CONTRA CD44v6 | |
| BR112013025629A2 (pt) | padrão quantitativo para espectrometria de massa de proteínas | |
| BR122018016031B8 (pt) | processo para produzir um anticorpo monoclonal variante com resposta de adcc realçada | |
| PH12021551627A1 (en) | Conjugate comprising ligand and ceacam5 antibody fab fragment | |
| MX2022012541A (es) | Inmunoconjugados. | |
| Chieng et al. | Clinical presentation of immune-related endocrine adverse events during immune checkpoint inhibitor treatment | |
| BR112012025681A2 (pt) | sistema e método para personalizar operações em tempo real em uma interface | |
| BR112013024686A2 (pt) | ensaio de psa, e, reagente de ensaio de psa | |
| NO20080928L (no) | Hoyniva grafikkstrom | |
| BR112021022171A2 (pt) | Anticorpo para tigit, seu uso e método para produzir o mesmo | |
| WO2018167141A3 (en) | Target detection using a monovalent antibody | |
| MX9307044A (es) | Polipetidos de afinidad modificada de anticuerpos que se unen a quelatos metalicos. | |
| BR112019002258A2 (pt) | anticorpo que se liga a pd-1 ou fragmento de ligação ao antígeno do anticorpo, método para produzir o mesmo e composição para prevenir ou tratar câncer | |
| AR118763A1 (es) | Anticuerpo monoclonal que se une específicamente a gitr | |
| CL2022000352A1 (es) | Método para la caracterización de polipéptidos que se unen a complejos de péptido:mhc | |
| Breen et al. | Bottom-up view of water network-mediated CO2 reduction using cryogenic cluster ion spectroscopy and direct dynamics simulations | |
| BR112016019739A2 (pt) | novo anticorpo de anti-presepsina | |
| MX2023014104A (es) | Anticuerpos especificamente unidos a la proteina asm. | |
| Burns et al. | HX‐MS 2 for high performance conformational analysis of complex protein states | |
| BR112022002376A2 (pt) | Anticorpos que se ligam especificamente à troponina t cardíaca humana, anticorpos, moléculas de ácido nucleico, vetor, composição e método para determinar a troponina t cardíaca humana | |
| Li et al. | A liquid chromatography/mass spectrometry-based generic detection method for biochemical assay and hit discovery of histone methyltransferases |